«We observed rapid and durable protective immunity
without adverse events, and so we think this candidate vaccine represents a promising strategy for the global fight
against Zika virus,» said senior author Drew Weissman, MD, PhD, a professor of
Infectious Disease at Penn. «We hope to start clinical trials in 12 to 18 months.»